In a recent article from the The Magazine of Weill Cornell Medical College and Weill Cornell Graduate School of Medical Sciences, physicians and scientists from the Lymphoma Program explained their approach to treating lymphoma. Dr. John Leonard explained,
“You shouldn’t treat everybody who walks in the door the same way. We want to treat with a tailored approach based on what’s most likely to work for that individual patient.”
Blood cancers have been at the forefront of research on tailored approaches to treatment, known as precision medicine. In large measure, these advancements are due to researchers’ ability to access tumor material from such patients more readily than they can with other types of cancer. In the past decade, Weill Cornell researchers have been involved in developing or testing almost every new lymphoma drug recently approved by the FDA. While most cancers today are treated primarily through surgery and radiation, Leonard notes, cancers of the blood are different. “Lymphoma is a disease where treating with drugs is central to curing the patient,” he says.
The entire article can be read here.